Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
暂无分享,去创建一个
G R Wilkinson | F. Greco | G. Wilkinson | F A Greco | K. Hande | K R Hande | S. Wolff | P J Wedlund | R M Noone | S N Wolff | P. Wedlund | R. Noone
[1] J. Loike,et al. Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. , 1976, Biochemistry.
[2] L. Benet,et al. Noncompartmental determination of the steady-state volume of distribution. , 1979, Journal of pharmaceutical sciences.
[3] D. Alberts,et al. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. , 1978, The New England journal of medicine.
[4] Tore Talseth,et al. Clinical Pharmacokinetics of Hydralazine , 1977 .
[5] B. Issell,et al. Etoposide (VP-16-213). , 1979, Cancer treatment reviews.
[6] N. Vogelzang,et al. VP-16-213 (etoposide): the mandrake root from Issyk-Kul. , 1982, The American journal of medicine.
[7] P. Creaven,et al. EPEG, a new antineoplastic epipodophyllotoxin , 1975, Clinical pharmacology and therapeutics.
[8] J. Hainsworth,et al. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Strife,et al. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography. , 1980, Journal of chromatography.
[10] J. Loike,et al. Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. , 1976, Biochemistry.
[11] Herzig Gp. Autologous marrow transplantation for cancer therapy. , 1981 .
[12] N. Nissen,et al. Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213). , 1972, Cancer chemotherapy reports.
[13] P. Bunn,et al. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. , 1979, Cancer treatment reports.
[14] P. Creaven,et al. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. , 1975, European journal of cancer.